Fennec Pharmaceuticals Inc. FENC 深 沪
等待开盘 11-13 09:30:00 美东时间
10.90
+0.260
+2.44%
华盛通- 最 高11.6394
- 今 开10.725
- 成交量 28.48万股
- 最 低 10.26
- 昨 收 10.64
- 总市值 3.82亿
- 52周最高 13.25
- 市盈率 静 --
- 换手率 0.81%
- 52周最低 5.65
- 委 比 19.84%
- 总股本 3506.72万
- 历史最高 14.986
- 量 比 1.37
- 振 幅 12.96%
- 历史最低 3.255
- 每 手 1
- 风险率 1.72%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Fennec Pharmaceuticals shares are trading higher after the company reported better-than-expected Q3 financial results.
Fennec Pharmaceuticals shares are trading higher after the company reported better-than-expected Q3 financial results.
11-12 23:47
Fennec Pharmaceuticals Q3 2026 Earnings Call Transcript
Fennec Pharmaceuticals (NASDAQ:FENC) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below. This transcript is brought to you by Benzinga APIs. For real-time access to our entire catalog, please visit https://www.b...
11-12 22:30
Fennec Pharmaceuticals Q3 EPS $0.12 Beats $0.10 Estimate, Sales $19.608M Beat $18.401M Estimate
Fennec Pharmaceuticals (NASDAQ:FENC) reported quarterly earnings of $0.12 per share which beat the analyst consensus estimate of $0.10 by 20 percent. This is a 700 percent increase over losses of $(0.02) per share from the same period last year. The company reported quarterly sales of $19.608 millio...
11-12 19:14
FENNEC PHARMACEUTI COM NPV收涨10.4%，成交额260.76万美元
11月10日，FENNEC PHARMACEUTI COM NPV（FENC）收涨10.4%，报10.83美元，成交额260.76万美元，市值3.8亿美元。 行...
11-10 07:17
Fennec Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 12, 2026
Fennec Pharmaceuticals Inc. will release its third quarter 2026 financial results on November 12, 2026, followed by a conference call and webcast at 8:30 a.m. ET. The webcast link is available on www.fennecpharma.com. Fennec focuses on reducing cisplatin-induced ototoxicity in cancer patients through PEDMARK®/PEDMARQSI®, which has received approvals in the U.S., Europe, and the U.K. The company has an exclusive licensing agreement with Norgine Ph...
11-06 10:50
FENNEC PHARMACEUTI COM NPV收涨2.93%，成交额190.84万美元
11月3日，FENNEC PHARMACEUTI COM NPV（FENC）收涨2.93%，报10.54美元，成交额190.84万美元，市值3.7亿美元。 行情...
11-03 07:15
FENNEC PHARMACEUTI COM NPV收涨0.69%，成交额117.43万美元
10月27日，FENNEC PHARMACEUTI COM NPV（FENC）收涨0.69%，报10.15美元，成交额117.43万美元，市值3.56亿美元。...
10-27 06:19
FENNEC PHARMACEUTI COM NPV收跌3.57%，成交额130.33万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 06:22
Fennec Pharmaceuticals Announces Oral Presentation of Detailed Results from Investigator-Initiated Phase 2 STS-J01 Clinical Study of Pedmark® in Japan at SIOP 2026
Fennec Pharmaceuticals announced positive results from the STS-J01 clinical trial evaluating PEDMARK® for reducing cisplatin-induced ototoxicity in pediatric and AYA patients in Japan. The study enrolled 33 patients, with 24.0% experiencing ASHA-defined hearing loss, significantly below the historical benchmark of 56.4% (P=0.001). No Grade 3 or 4 hearing loss was observed, and objective tumor responses were seen in 95.8% of evaluable patients. Pr...
09-17 11:30
美股大行评级 | 戴尔、Adobe获大行上调目标价；甲骨文绩前目标价遭调低
今日重点评级关注：富国银行：维持Pyxis Oncology"超配"评级，目标价从12美元升至19美元；Oppenheimer：维持Opus Genetics"跑赢大市"评级，目标价从10美元升至20美元
09-10 15:00
